DN-1508052 is under clinical development by Shanghai De Novo Pharmatech and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase I drugs for Transitional Cell Cancer (Urothelial Cell Cancer) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DN-1508052’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DN-1508052 overview
DN-1508052 is under development for the treatment of solid tumors including recurrent or metastatic head and neck squamous cell carcinoma oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer small cell lung cancer, non-small cell lung cancer, triple negative breast cancer, cervical cancer, urothelial cancer, melanoma, primary hepatocellular carcinoma, colorectal cancer HPV-related cancers, including oropharyngeal cancer, cervical cancer, prostate cancer, bladder cancer, penile cancer, anal cancer, nasopharyngeal cancer, metastatic melanoma, metastatic breast cancer, metastatic colorectal cancer, human epidermal growth factor receptor 2 negative breast cancer (her2- breast cancer), soft tissue sarcoma, osteosarcoma, leiomyosarcoma, pleomorphic liposarcoma, synovial sarcoma, ewing sarcoma and head and neck cancer, adenocarcinoma of the gastroesophageal junction, neuroendocrine tumors, bile duct cancer (cholangiocarcinoma). It is a new chemical entity. It is administered through subcutaneous route. The drug candidate acts by targeting toll-like receptor (TLR-8).
It was under development for leukemia and chondrosarcoma.
For a complete picture of DN-1508052’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
